Soetomo COVID-19 Prognostic Score: A Multi-Parametric Model for Early Prediction of Disease Severity of COVID-19 in Tertiery -Resource Hospital
DOI:
https://doi.org/10.31584/jhsmr.20241044Keywords:
COVID-19, human and health, prognostic model, scoring systemAbstract
Objective: Coronavirus disease 2019 (COVID-19) became a global pandemic, with high mortality in severely ill patients. This study aimed to develop a novel scoring system to prognosticate disease severity in COVID-19 patients that is effective and widely available in tertiary medical resource settings.
Material and Methods: Laboratory-confirmed COVID-19 patients were enrolled in this retrospective cohort, divided into severe and non-severe groups. We randomly assigned 70% of the subjects to establish a novel scoring system, while the remaining 30% was used for internal validation. The model was constructed by multivariate logistic regression using the first clinical, laboratory, and radiological finding of statistically analysis of group patients. receiver operating characteristic (ROC) and cross-tabulation were used to evaluate the performance of our score and compare it with other models.
Results: A total of 599 patients were included. The Soetomo COVID-19 prognostic score predictors included age, fever, specific comorbidities (diabetes, hypertension, cardiac disease, lung tuberculosis), respiratory rate, heart rate, SF ratio, whole blood cell (WBC) count, neutrophil lympocyte ratio (NLR), blood urea nitrogen (BUN), and a RALE score. The area under the ROC of the model indicated an excellent discriminatory ability (training datasets 0.715 [95% CI 0.664-0.767, p-value<0.001]; testing datasets 0.720 [95% CI 0.638-0.802, p-value<0.001]). Our scoring system was superior to both qSOFA and MEWS regarding predictive value. The sensitivity and specificity were 60.6% and 82.5%, respectively.
Conclusion: The developed scoring system accurately predicted a significant proportion of severe disease in COVID-19 patients.
References
WHO. Coronavirus Disease (COVID-19) Situation Reports. 2021. [homepage on the Internet]. Jakarta: WHO; [cited 2021]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
WHO. Situation Report-7 INDONESIA Situation Report 19 Internal for SEARO. 2021. [homepage on the Internet]. Jakarta: WHO; [cited 2021 Jul 14]. Available from: https://setkab.go.id/en/govt-to-extend-ppkm-implementation-in-7-provinces/
Sun P, Lu X, Xu C, Sun W, Pan B. Understanding of COVID-19 based on current evidence. J Med Virol 2020;92:548–51.
Fahmi M, Kharisma VD, Ansori ANM, Ito M. Retrieval and Investigation of Data on SARS-CoV-2 and COVID-19 Using Bioinformatics Approach. Adv Exp Med Biol 2021;839–57.
Clark A, Jit M, Warren-Gash C, Guthrie B, Wang HHX, Mercer SW, et al. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modeling study. Lancet Glob Heal 2020;8:e1003–17.
Clark A, Jit M, Warren-Gash C, Guthrie B, Wang HHX, Mercer SW, et al. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modeling study. Lancet Glob Heal 2020;8:e1003–17.
European Centre for Disease Prevention and Control. The European Surveillance System (TESSY). [homepage on the Internet]. Stockholm: European Centre for Disease Prevention and Control; 2017 [cited 2021]. Available from: www.ecdc.europa.eu/en/publications-data/european-surveillance-system-tessy
WHO. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern 2021. [homepage on the Internet]. Geneva: WHO; 2021 [cited 2021]. Available from: www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern
Ito N, Kitahara Y, Miwata K, Okimoto M, Takafuta T. Can the Omicron variant of COVID-19 cause pneumonia in young patients without risk factors? Clin Case Reports 2022;10:e05684.
MoH. Prevention and control guidelines of corona virus disease (COVID-19). Jakarta: Ministry of Health. Indonesian Directorate General of Disease Prevention and Control. 2020.
Warren MA, Zhao Z, Koyama T, Bastarache JA, Shaver CM, Semler MW, et al. The severity scoring of lung edema on the chest radiograph is associated with clinical outcomes in ARDS. Thorax 2018;73:840–6.
Seymour CW, Liu VX, Iwashyna TJ, Brunkhorst FM, Rea TD, Scherag A, et al. Assessment of clinical criteria for sepsis: for the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016;315:762–74.
Subbe CP, Kruger M, Rutherford P, Gemmel L. Validation of a modified Early Warning Score in medical admissions. QJM 2001;94:521–6.
Yu C, Lei Q, Li W, Wang X, Liu W, Fan X, et al. Clinical characteristics, associated factors, and predicting COVID-19 mortality risk: a retrospective study in Wuhan, China. Am J Prev Med 2020;59:168–75.
Wahyuni DK, Wacharasindhu S, Bankeeree W, Punnapayak H, Purnobasuki H, Junairiah J, et al. Molecular simulation of compounds from n-hexane fraction of Sonchus arvensis L. leaves as SARS-CoV-2 antiviral through inhibitor activity targeting strategic viral protein. J Pharm Pharmacogn Res 2022;10:1126–38.
Starr M. Sepsis in old age: review of human and animal studies. Aging Dis. 2014;5:126–36.
Zheng X, Chen J, Deng L, Fang Z, Chen G, Ye D, et al. risk factors for the COVID-19 severity and its correlation with viral shedding: a retrospective cohort study. J Med Virol 2021;93:952–61.
Canna SW, Behrens EM. Making sense of the cytokine storm: a conceptual framework for understanding, diagnosing, and treating hemophagocytic syndromes. Pediatr Clin 2012;59:329–44.
National report on basic health research. [Riskesdas]. MoH. National report on basic health research. Jakarta: Ministry of Health; 2018.
Kumar A, Arora A, Sharma P, Anikhindi SA, Bansal N, Singla V, et al. Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. Diabetes Metab Syndr Clin Res Rev 2020;14:535–45.
Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol 2020;109:531–8.
Okoduwa SIR, Mhya DH, Enang IA, Salawu AO. Diabetes mellitus and COVID-19: possible interactions and mechanisms in comorbid patients. J Health Sci Med Res 2023;41:e2022904.
De Lorenzo A, Escobar S, Tibiriçá E. Systemic endothelial dysfunction: a common pathway for COVID-19, cardiovascular and metabolic diseases. Nutr Metab Cardiovasc Dis 2020;30:1401–2.
Gao Y, Liu M, Chen Y, Shi S, Geng J, Tian J. Association between tuberculosis and COVID-19 severity and mortality: a rapid systematic review and meta-analysis. J Med Virol 2021;93:194–6.
Sy KTL, Haw NJL, Uy J. Previous, and active tuberculosis increases the risk of death and prolongs recovery in patients with COVID-19. Infect Dis (Auckl) 2020;52:902–7.
Berger T, Green J, Horeczko T, Hagar Y, Garg N, Suarez A, et al. Shock index and early recognition of sepsis in the emergency department: pilot study. West J Emerg Med 2013;14:168.
Serpa Neto A, Cardoso SO, Ong DSY, Espósito DC, Pereira VG, Manetta JA, et al. The use of the pulse oximetric saturation/fraction of inspired oxygen ratio for risk stratification of patients with severe sepsis and septic shock. J Crit Care 2013;28:681–6.
Fukuda Y, Tanaka A, Homma T, Kaneko K, Uno T, Fujiwara A, et al. Utility of SpO2/FiO2 ratio for acute hypoxemic respiratory failure with bilateral opacities in the ICU. Zivkovic AR, editor. PLoS One 2021;16:e0245927.
Rice TW, Wheeler AP, Bernard GR, Hayden DL, Schoenfeld DA, Ware LB. Comparison of the Sp o 2 /F io 2 ratio and the Pa o 2 /F io 2 ratio in patients with acute lung injury or ARDS. Chest 2007;132:410–7.
Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med 2020;58:1021–8.
Muhammad Ansori AN, Kharisma VD, Fadholly A, Rani Tacharina M, Antonius Y, Parikesit AA. Severe acute respiratory syndrome Coronavirus-2 Emergence and Its Treatment with alternative medicines: a review. Res J Pharm Technol 2021;5551–7.
Li X, Liu C, Mao Z, Xiao M, Wang L, Qi S, et al. Predictive values of neutrophil-to-lymphocyte ratio on disease severity and mortality in COVID-19 patients: a systematic review and meta-analysis. Crit Care 2020;24:1–10.
Muhammad Ansori AN, Dhea Kharisma V, Sabilil Muttaqin S, Antonius Y, Parikesit AA. Genetic Variant Of SARS-CoV-2 isolates in indonesia: spike glycoprotein gene. J Pure Appl Microbiol 2020;14(suppl 1):S971–8.
Cheng A, Hu L, Wang Y, Huang L, Zhao L, Zhang C, et al. Diagnostic performance of initial blood urea nitrogen combined with D-dimer levels for predicting in-hospital mortality in COVID-19 patients. Int J Antimicrob Agents 2020;56:106110.
Zu ZY, Jiang M Di, Xu PP, Chen W, Ni QQ, Lu GM, et al. Coronavirus disease 2019 (COVID-19): a perspective from China. Radiology 2020;296:E15–25.
Lyu P, Liu X, Zhang R, Shi L, Gao J. The performance of chest ct in evaluating the clinical severity of COVID-19 pneumonia: identifying critical cases based on ct characteristics. Invest Radiol 2020;55.
Ciceri F, Castagna A, Rovere-Querini P, De Cobelli F, Ruggeri A, Galli L, et al. Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy. Clin Immunol 2020;217:108509.
Aslam S SM, Suhail K M, Kulkarni A. Clinical and epidemiological characteristics of elderly patients with coronavirus disease-19 at a tertiary care center in South India. J Heal Sci Med Res 2023;41:e2023963.
Sapey E, Gallier S, Mainey C, Nightingale P, McNulty D, Crothers H, et al. Ethnicity and risk of death in patients hospitalized for COVID-19 infection in the UK: an observational cohort study in an urban catchment area. BMJ Open Respir Res 2020;7:e000644.
Price-Haywood EG, Burton J, Fort D, Seoane L. Hospitalization and mortality among black patients and white patients with Covid-19. N Engl J Med 2020;382:2534–43.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
